NextCell Pharma

The Rights Issue in summary:

• Subscription period: 31 May 2024 – 14 June 2024.
• Trading in unit rights: 31 May 2024 – 11 June 2024.
• Preferential rights: For each (1) share held on the record date on 29 May 2024, eleven (11) unit rights are received, and ten (10) unit rights entitle to subscription of one (1) unit.
• Unit: One (1) unit consists of one (1) newly issued share and one (1) warrant of series TO2.
• Subscription price: SEK 1.06 per unit, corresponding to SEK 1.06 per share. The warrants are issued free of charge.
• Proceeds: Upon full subscription in the Rights Issue, the Company will receive proceeds of approximately SEK 40.1 million before deduction of issue costs. Upon full exercise of the warrants of series TO2, the Company may receive an additional of up to approximately SEK 113.5 million before deduction of issue costs, provided full subscription of the Rights Issue.
• Subscription undertakings and guarantee commitments: In total, the Rights Issue is covered to approximately 80 percent by subscription undertakings and guarantee commitments, corresponding to approximately SEK 32.1 million. If the Rights Issue is subscribed to more than 80 percent, the guarantee commitments will not be called upon.

For complete information on the terms and conditions of the Rights Issue, reference is made to the prospectus published by the Company on 30 May 2024 by reason of the Rights Issue (the “Prospectus”). The Prospectus is available on the Company’s website, www.nextcellpharma.com, Redeye’s website, www.redeye.se, and the Swedish Financial Supervisory Authority’s website, www.fi.se.
 

Timetable for the Rights Issue

Advisors

Redeye AB is financial advisor to NextCell in connection with the Rights Issue. Törngren Magnell & Partners Advokatfirma KB is legal advisor to the Company in connection with the Rights Issue.